Details

Autor(en) / Beteiligte

• Bae, Ki Hyun
• Tan, Susi
• Yamashita, Atsushi
• Ang, Wei Xia
• Gao, Shu Jun
• Wang, Shu
• Chung, Joo Eun
• Kurisawa, Motoichi

Titel

Hyaluronic acid-green tea catechin micellar nanocomplexes: Fail-safe cisplatin nanomedicine for the treatment of ovarian cancer without off-target toxicity

Ist Teil von

• Biomaterials, 2017-12, Vol.148, p.41-53

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2017

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The green tea catechin, (–)-epigallocatechin-3-O-gallate (EGCG), has gained significant attention as a potent adjuvant to enhance the antitumor efficacy of cisplatin while mitigating its harmful side effects. Herein we report the development of a fail-safe cisplatin nanomedicine constructed with hyaluronic acid-EGCG conjugate for ovarian cancer therapy. A simple mixing of this conjugate and cisplatin induces spontaneous self-assembly of micellar nanocomplexes having a spherical core-shell structure. The surface-exposed hyaluronic acid enables efficient delivery of cisplatin into CD44-overexpressing cancer cells via receptor-mediated endocytosis whereas the internally packed EGCG moieties offer an environment favorable for the encapsulation of cisplatin. In addition, the antioxidant effect of EGCG moieties ensures fail-safe protection against off-target organ toxicity originating from cisplatin-evoked oxidative stress. Pharmacokinetic and biodistribution studies reveal the prolonged blood circulation and preferential tumor accumulation of intravenously administered nanocomplexes. Moreover, the nanocomplexes exhibit superior antitumor efficacy over free cisplatin while displaying no toxicity in both a subcutaneous xenograft model and peritoneal metastatic model of human ovarian cancer. Our findings demonstrate proof of concept for the feasibility of green tea catechin-based micellar nanocomplexes as a safe and effective cisplatin nanomedicine for ovarian cancer treatment. [Display omitted] •Hyaluronic acid-green tea catechin micellar nanocomplexes for ovarian cancer therapy.•A novel strategy to avoid off-target toxicity of cisplatin in healthy organs.•Targeted delivery of cisplatin into CD44-overexpressing cancer cells.•Superior in vivo antitumor efficacy over free cisplatin without severe toxicities.